Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function.
This cross-sectional study was to compare glycemic control, kidney function, vascular function, cerebrovascular function, physical fitness and quality of life between elderly with diabetic kidney disease who practiced Thai dance meditation training and normal daily life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
40
Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
No intervention
Faculty of Sports Science, Chulalongkorn University
Pathum Wan, Bangkok, Thailand
Blood pressure
Blood pressure (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) in mmHg will be measured with automated blood pressure in mmHg device (CARESCAPE V100, GE Dinamap).
Time frame: Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]
Heart rate
Heart rate in beats per minute will be measured with automated blood pressure in beat per minute device (CARESCAPE V100, GE Dina map).
Time frame: Change from baseline heart rate at 12 weeks
Body fat
Body fat in percent will be measured with dual energy x-ray absorptiometry in percent (Prodigy-Pro, GE healthcare).
Time frame: Change from baseline body fat at 12 weeks
Muscle mass and Weight
Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry in kilogram (Prodigy-Pro, GE healthcare).
Time frame: Change from baseline muscle mass and weight at 12 weeks.
Arterial stiffness
Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare).
Time frame: Change from baseline brachial-ankle pulse wave velocity at 12 weeks
Macro vascular function
Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment EPIQ 5G, Phillips.
Time frame: Change from baseline brachial artery flow-mediated dilatation at 12 weeks
Renal function
Blood urea nitrogen (BUN) in milligram per deciliter will be measure by Kinetic test with urease and glutamate dehydrogenase with urease/glutamate dehydrogenase coupled enzymatic (Coupled enzymes)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Change from baseline Blood urea nitrogen at 12 weeks.
Intrarenal artery
Intrarenal artery will be measured by renal blood flow in renal arterial resistive index (RI) with ultrasonography equipment EPIQ 5G, Phillips.
Time frame: Change from baseline renal arterial resistive index (RI) at 12 weeks.
Post Occlusive Reactive Hyperemia; PORH
Evaluation of blood flow to the skin area in percent will be measured by Post Occlusive Reactive Hyperemia in percent; PORH with Laser Doppler flowmeter, Perimed AB, Sweden.
Time frame: Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks.
Cerebral blood flow
Cerebral blood flow in centimeter per second will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Time frame: Change from baseline cerebral blood flow at 12 weeks
Cerebrovascular conductance index
Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Time frame: Change from baseline cerebrovascular conductance index at 12 weeks
Cerebrovascular reactivity index
Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips).
Time frame: Change from baseline cerebrovascular reactivity index at 12 weeks
Arterial compliance
Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare).
Time frame: Change from baseline Arterial compliance at 12 weeks
Pulsatility index
Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips).
Time frame: Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment
Montreal Cognitive Assessment
Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Time frame: Change from baseline Montreal Cognitive Assessment at 12 weeks.]
Mini-Mental State Examination
Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function.
Time frame: Change from baseline Mini-Mental State Examination at 12 weeks.]
Trail Making Test-B
Trail Making Test-B in second cut off below 101 seconds that indicate dementia.
Time frame: Change from baseline Trail Making Test-B at 12 weeks
Fasting blood sugar
Fasting blood sugar in mg/dl will be measure with enzymatic assay using hexokinase reaction.
Time frame: Change from baseline fasting blood sugar at 12 weeks.]
Glycosylated hemoglobin
Glycosylated hemoglobin in percent will be measure with enzymatic assay using hexokinase reaction.
Time frame: Change from baseline Glycosylated hemoglobin at 12 weeks.]
Homeostasis Model Assessment of insulin resistance
Homeostasis Model Assessment of insulin resistance in units will be calculated with Fasting blood sugar and insulin.
Time frame: Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.]
Creatinine
Creatinine in mg/dl will be measure with enzymatic assay
Time frame: Change from baseline creatinine at 12 weeks.]
estimate Glomerular filtration rate
estimate Glomerular filtration rate in ml/min/1.73 m2 will be calculated by CKD-EPI formular according to National kidney foundation recommendation.
Time frame: Change from baseline estimate Glomerular filtration rate at 12 weeks.]
Cystatin C
Cystatin C in mg/L will be measure with particle enhanced Immunoturbidimetric assay
Time frame: Change from baseline blood urea nitrogen at 12 weeks
Urine albumin creatinine ratio
Urine albumin creatinine ratio will be measure with Immunoturbidimetric assay
Time frame: Change from baseline urine albumin creatinine ratio at 12 weeks.
Stroop test
Stroop test in second will be measured with EncephalApp - Stroop Test
Time frame: Change from baseline Stroop test in second at 12 weeks.
Waist circumference
Waist circumference in inch will be measure by waist tape
Time frame: Change from baseline waist circumference at 12 weeks]
.Flexibility testing
Flexibility testing will be measure by Chair sit \& reach protocol in centimeters.
Time frame: Change from baseline Chair sit & reach at 12 weeks.]
Muscle strength testing
Muscle strength testing will be measured by arm-curl test repetitions in 30 seconds
Time frame: Change from baseline arm-curl and chair stand at 12 weeks.]
Muscle strength testing
Muscle strength testing will be measured by arm-curl test and chair stand test in repetitions in 30 seconds
Time frame: Change from baseline arm-curl and chair stand at 12 weeks.]
Balance testing
Balance testing will be measured by time up and go testing in seconds.
Time frame: Change from baseline time up and go at 12 weeks.]
Cardiopulmonary fitness
Cardiopulmonary fitness will be measure by 6-minutes walk test in meters.
Time frame: Change from baseline 6-minutes walk at 12 weeks.]
Lipid profile
Lipid profile will be measure by cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein in mg/dl.
Time frame: Change from baseline Nitric oxide at 12 weeks.] cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein at 12 weeks.]
Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase.
Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase in pg/ml will be measure with ELISA assay kit.
Time frame: Change from baselineInterleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase. at 12 weeks.]
Nitric oxide
Nitric oxide in µM will measured with standard Griess reagents.
Time frame: Change from baseline Nitric oxide at 12 weeks.
Quality of life in patients with chronic kidney disease
Quality of life will be measured by SF-36 questionnaire for evaluation of Quality of Life in patients with chronic kidney disease. The scores of questionnaires were 75-100 points for good quality of life, 50-75 points for moderate quality of life, 25-50 points for low quality of life and 0-25 points for very low quality of life.
Time frame: Change from baseline at 12 weeks.
Flexibility testing
Flexibility testing will be measure by back scratch in centimeters.
Time frame: Change from baseline back scratch at 12 weeks.
Muscle strength testing
Muscle strength testing will be measured by chair stand test in repetitions in 30 seconds
Time frame: Change from baseline chair stand at 12 weeks.]
Body mass index (BMI)
Body mass index (BMI) through height and weight measurement by body composition analyzer weight and height will be combined to report BMI in kg/m\^2.
Time frame: Change from baseline BMI at 12 weeks.